Official Logo
Gold Kiddos
An Advocacy e-Bulletin to Strengthen Our Community
Dear Childhood Cancer Advocate:


The Best Pharmaceuticals for Children Act (BPCA) and Pediatric Research Equity Act (PREA) are two critical federal laws that provide incentives and requirements for pharmaceutical companies to test their drugs for use in children. BPCA and PREA expire on October 1, 2012, and Congress is currently working to reauthorize these laws in advance of their sunset date.


While BPCA and PREA have made significant research advances in how medicines can be used in children in general, the laws have had a very modest impact on the development of new drugs for children with cancer. In fact, PREA itself has had no meaningful impact. We need your help to modify this law so that it can help children with cancer. 

Under current PREA law, companies are required to study their drugs in children only if the drug is developed for a disease that occurs in both adults and children. Because common adult cancers - such as breast, colon, lung and prostate typically do not affect children, companies receive waivers so they are not required to study these drugs in children with cancer even though they may hold great promise.


The American Childhood Cancer Organization is partnering with The Children's Cause for Cancer Advocacy, The Alliance for Childhood Cancer, and the Children's Oncology Group (COG) to advocate for a proposal  to strengthen PREA so that it can be used to encourage companies to evaluate whether their new cancer drugs can provide better and more effective treatment options for children with cancer "if the target of the drug for an adult oncologic indication is included in the drug's label and is highly relevant to any pediatric cancer to which it could apply."


Please take action today by contacting your Representatives and Senators to urge them to strengthen PREA for children with cancer. To see the language proposed for PREA that will advance therapies for children with cancer, and to send a letter to your Members of Congress, click this link.


Thank you for adding your voice to this critical effort to help improve treatments for our children.
Ruth I Hoffman MPH
Executive Director


American Childhood Cancer Organization
10920 Connecticut Avenue, Suite A
Kensington, MD 20895
855-858-ACCO (2226)
Like us on Facebook View our videos on YouTube Follow us on Twitter